METHOD FOR FREEZING CELL STRUCTURE

The present invention relates to a method for freezing a cell structure including freezing a cell structure including fragmented extracellular matrix components, cells and fibrin and having a three-dimensional tissue structure.

CELL CONSTRUCT AND CELL CONSTRUCT PRODUCTION METHOD

Disclosed is a cell construct that contains a fragmented extracellular matrix component and cells and that has an intercellular vascular network, wherein the cells include at least fat cells and vascular endothelial cells.

METHOD FOR FREEZING CELL STRUCTURE

The present invention relates to a method for freezing a cell structure, the method comprising freezing a cell structure that contains a fragmented extracellular matrix component, a cell, and fibrin, and that has a three-dimensional organizational structure.

METHOD FOR PRODUCING THREE-DIMENSIONAL TISSUE BODY AND METHOD FOR PROMOTING DIFFERENTIATION OF ADIPOSE-DERIVED STEM CELLS

A method for producing a three-dimensional tissue construct comprising mature adipocytes, comprising incubating cells comprising at least fat-derived stem cells in the presence of one or more fatty acids selected from the group consisting of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid.

SCHWANN CELLS AND METHOD FOR PREPARING SAME

The present invention addresses the problem of providing a method for obtaining Schwann cells directly (by direct reprogramming) without passing through pluripotent stem cells, such as ES cells or iPS cells. As a means for solving this problem, the present invention provides a method for preparing Schwann cells that includes a step of introducing into somatic cells of a mammal at least one gene selected from the group consisting of SOX10 genes and KROX20 genes, or an expression product thereof. 1. A method for preparing a Schwann cell comprising introducing into a somatic cell of a mammal at least one gene selected from the group consisting of SOX10 and KROX20 genes , or an expression product thereof.2. The method according to claim 1 , wherein the gene is a combination of SOX10 and KROX20 genes.3. The method according to claim 1 , wherein the somatic cell is a fibroblast claim 1 , a vascular endothelial cell claim 1 , or a mesenchymal stem cell.4. A Schwann cell derived from a somatic cell of a mammal claim 1 , the cell comprising at least one gene selected from the group consisting of exogenous SOX10 and KROX20 genes claim 1 , or an expression product thereof.5. A grafting material for treating a disease based on a nerve defect claim 1 , or a defect claim 1 , deficiency claim 1 , or hypofunction of Schwann cells claim 1 , the grafting material comprising a cell obtained by the method according to .6. A composition for preparing a Schwann cell claim 1 , the composition comprising at least one gene selected from the group consisting of SOX10 and KROX20 genes claim 1 , or an expression product thereof.7. The method according to claim 2 , wherein the somatic cell is a fibroblast claim 2 , a vascular endothelial cell claim 2 , or a mesenchymal stem cell.8. A grafting material for treating a disease based on a nerve defect claim 2 , or a defect claim 2 , deficiency claim 2 , or hypofunction of Schwann cells claim 2 , the grafting material comprising a cell obtained by ...

CELL PREPARATION METHOD

Provided is a method of preparing a somatic cell including converting a differentiated somatic cell of a mammal to other somatic cell by culturing the differentiated somatic cell in a medium for inducing differentiation of the somatic cell other than the differentiated somatic cell in the presence of a TGF-β pathway inhibitor. 1. A method of generating a somatic cell comprising converting a differentiated somatic cell of a mammal to other somatic cell by culturing the differentiated somatic cell in a medium for inducing a somatic cell other than the aforementioned differentiated somatic cell in the presence of a TGF-β pathway inhibitor.2. The method according to claim 1 , wherein the TGF-β pathway inhibitor is a D4476 claim 1 , SB431542 claim 1 , LY2157299 claim 1 , SD208 or ALK5 inhibitor II.3. The method according to claim 1 , wherein the TGF-β pathway inhibitor is an ALK5 inhibitor II.4. The method according to claim 1 , wherein the fibroblast is converted to a mesenchymal cell.5. The method according to claim 1 , wherein the fibroblast or keratinocyte is converted to an osteoblast.6. The method according to claim 1 , wherein the fibroblast or peripheral blood mononuclear cell is converted to a white adipocyte.7. The method according to claim 1 , wherein the fibroblast or keratinocyte is converted to a brown adipocyte.8. The method according to claim 6 , wherein the medium for inducing differentiation of the somatic cell comprises a Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) agonist.9. The method according to claim 1 , wherein the fibroblast is converted to a chondrocyte.10. The method according to claim 1 , wherein the fibroblast is converted to a myoblast.11. The method according to claim 1 , wherein the fibroblast is converted to a Schwann cell.12. The method according to claim 1 , wherein the keratinocyte is converted to a urothelial cell.13. The method according to claim 1 , wherein the fibroblast is converted to a mesenchymal stem cell.1415-. ( ...

CELL CONSTRUCT AND CELL CONSTRUCT PRODUCTION METHOD

Disclosed is a cell structure comprising: a fragmented extracellular matrix component; and cells, wherein the cell structure comprises an intercellular vascular network, and the cells comprise at least adipocytes and vascular endothelial cells. 1. A cell structure comprising: a fragmented extracellular matrix component; and cells , whereinthe cell structure comprises an intercellular vascular network, andthe cells comprise at least adipocytes and vascular endothelial cells.2. The cell structure according to claim 1 , wherein the vascular network is formed among the adipocytes.3. The cell structure according to or claim 1 , wherein the adipocytes comprise mature adipocytes.4. The cell structure according to any one of to claim 1 , wherein an average length of the fragmented extracellular matrix component is 100 nm or more and 400 μm or less.5. The cell structure according to any one of to claim 1 , wherein a content of the extracellular matrix component in the cell structure is 0.01 to 90% by mass based on a dry mass of the cell structure.6. The cell structure according to any one of to claim 1 , wherein the fragmented extracellular matrix component comprises collagen.7. The cell structure according to any one of to claim 1 , further comprising fibrin.8. The cell structure according to any one of to claim 1 , for transplantation.9. A method for producing a cell structure comprising an intercellular vascular network claim 1 , the method comprising:a contacting step of bringing a fragmented extracellular matrix component and cells into contact with each other, wherein the cells (i) comprise at least adipocytes, stem cells, and vascular endothelial cells, or (ii) comprise at least adipose stem cells and vascular endothelial cells; anda culturing step of culturing the cells that are in contact with a fragmented extracellular matrix.10. The method according to claim 9 , wherein the cells comprise adipocytes claim 9 , adipose stem cells claim 9 , and vascular endothelial ...

Schwann cells and method for preparing same

放射線障害防護剤

【課題】新規な放射線障害防護剤を提供すること。【解決手段】脂肪組織又は脂肪組織由来産物（例えば、間質血管画分（Ｓｔｒｏｍａｌ ｖａｓｃｕｌａｒ ｆｒａｃｔｉｏｎ；ＳＶＦ）、細片化脂肪組織マトリックス（ｍｉｃｒｏｎｉｚｅｄ ｃｅｌｌｕｌａｒ ａｄｉｐｏｓｅ ｍａｔｒｉｘ；ＭＣＡＭ）、または脂肪由来幹細胞（Ａｄｉｐｏｓｅ－ｄｅｒｉｖｅｄ ｓｔｅｍ／ｓｔｒｏｍａｌ ｃｅｌｌ；ＡＳＣ））を含む、放射線障害防護剤。【選択図】なし

Cell preparation method

Provided is a method of preparing a somatic cell including converting a differentiated somatic cell of a mammal to other somatic cell by culturing the differentiated somatic cell in a medium for inducing differentiation of the somatic cell other than the differentiated somatic cell in the presence of a TGF-β pathway inhibitor.

Method for freezing cell structure

The present invention relates to a method for freezing a cell structure including freezing a cell structure including fragmented extracellular matrix components, cells and fibrin and having a three-dimensional tissue structure.

Cell preparation method

Provided is a method of preparing a somatic cell including converting a differentiated somatic cell of a mammal to other somatic cell by culturing the differentiated somatic cell in a medium for inducing differentiation of the somatic cell other than the differentiated somatic cell in the presence of a TGF-β pathway inhibitor.

Method for freezing cell structure

Method for producing three-dimensional tissue body and method for promoting differentiation of adipose-derived stem cells

A method for producing a three-dimensional tissue construct comprising mature adipocytes, comprising incubating cells comprising at least fat-derived stein cells in the presence of one or more fatty acids selected from the group consisting of erucic acid, elaidic acid, oleic acid, palmitoleic acid, myristoleic acid, phytanic acid, and pristanic acid.

Method for producing three-dimensional tissue body and method for promoting differentiation of adipose-derived stem cells

Verfahren zum screenen nach gegen krebs gerichteten medikamenten

Method for screening anticancer agent

By analyzing the mechanism for inducing a histone deacetylase inhibitor (Trichostatin A) -mediated expression of cyclin-CDK inhibitory factor having a proliferation suppressing effect (tumor-suppressing effect) , it was revealed that the binding of Sp3 to the Sp1 binding sequence within a promoter is important in the expression of the above factor. Thus, a novel antitumor agent can be developed by screening a pharmaceutical agent capable of elevating Sp3 activity.

Method for screening anticancer agent

By analyzing the mechanism for inducing a histone deacetylase inhibitor (Trichostatin A) -mediated expression of cyclin-CDK inhibitory factor having a proliferation suppressing effect (tumor-suppressing effect) , it was revealed that the binding of Sp3 to the Sp1 binding sequence within a promoter is important in the expression of the above factor. Thus, a novel antitumor agent can be developed by screening a pharmaceutical agent capable of elevating Sp3 activity.

Verfahren zum screenen nach gegen krebs gerichteten medikamenten

Method for screening anticancer agent

By analyzing the mechanism for inducing a histone deacetylase inhibitor (Trichostatin A) -mediated expression of cyclin-CDK inhibitory factor having a proliferation suppressing effect (tumor-suppressing effect) , it was revealed that the binding of Sp3 to the Sp1 binding sequence within a promoter is important in the expression of the above factor. Thus, a novel antitumor agent can be developed by screening a pharmaceutical agent capable of elevating Sp3 activity.

Method for producing organism, and method for promoting differentiation of human adipose-derived stem cells into vascular endothelial cells

There is provided a method for producing a tissue construct comprising vascular endothelial cells, the method comprising incubating cells comprising at least adipose-derived stem cells from human in the presence of a TGFβ type I receptor inhibitor.